Identification

Name
Hyaluronic acid
Accession Number
DB08818
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan distributed widely throughout connective, epithelial, and neural tissues. It is unique among glycosaminoglycans in that it is nonsulfated, forms in the plasma membrane instead of the Golgi, and can be very large, with its molecular weight often reaching the millions. One of the chief components of the extracellular matrix, hyaluronic acid contributes significantly to cell proliferation and migration, and may also be involved in the progression of some malignant tumors.

Structure
Thumb
Synonyms
  • Hyaluronan
  • Hyaluronate
Product Ingredients
IngredientUNIICASInChI Key
Hyaluronate sodiumNot AvailableNot AvailableNot applicable
Potassium hyaluronateNot Available31799-91-4Not applicable
Sodium hyaluronateYSE9PPT4TH9067-32-7Not applicable
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Deepair Micro Intensive MagicPatch6.1 g/100mgTopicalAcosmetic. co.ltd2016-08-01Not applicableUs
Hyaluron 3s SerumCream.15 g/50mLTopicalUlab2017-03-02Not applicableUs
Hyaluronic Acid GelGel3.5 mg/mLTopicalMeso System S A2016-12-14Not applicableUs
Hyaluronic Acid GelGel3.5 mg/mLTopicalMeso System S A2016-04-15Not applicableUs
Hyaluronic Acid MicroPatch1.14 g/41TopicalJunmok International,Inc2015-07-01Not applicableUs
HYLASE WoundGel2.5 g/100gTopicalECR Pharmaceuticals Co., Inc.2012-01-06Not applicableUs
Im FillPatch99.97 g/100gTopicalKaratica Co., Ltd2017-11-29Not applicableUs
Maxclinic Hyaluronic Meso Change RollerPatch67.9 mg/70mgTopicalN&b lab.co.ltd2016-12-20Not applicableUs
Maxclinic Hyaluronic Meso Change RollerPatch67.9 mg/70mgTopicalN&b lab.co.ltd2016-12-20Not applicableUs
MorisuSolution.01 mL/100mLTopicalKit Living Science Of Kyungnam College University Of Information & Technology2011-02-08Not applicableUs
International/Other Brands
AMO Vitrax / AMVISIC Plus / Cystistar / Euflexxa (Ferring) / Hyalart / Hyalgan (Fidia) / Hylo-Comod / Legend / Monovisc (Anika Therapeutics, Inc.) / Recosyn / Synvisc / Viscure / Yardel
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acropass Trouble CureHyaluronic acid (.53 mg/.58mg) + Nicotinamide (.03 mg/.58mg)PatchTopicalRaphas Co.,ltd2016-11-01Not applicableUs
bdr Laser Effect Peptide Complex Face MaskHyaluronic acid (.51 g/30g) + Tocopherol (.105 g/30g)PatchTopicalHanaim International Llc2016-11-22Not applicableUs
Clapiel Hyalon SerumHyaluronate sodium (10.5 mg/30mL) + Nicotinamide (.6 mg/30mL)CreamTopicalAus Korea Co., Ltd.2015-05-01Not applicableUs
Hyaluronic Acid 60mg and Lidocaine 2% PFHyaluronic acid (20 mg/mL) + Lidocaine hydrochloride (20 mg/mL)Injection, solutionIntra-articularUs Compounding, Inc2013-12-202015-12-29Us
Categories
UNII
S270N0TRQY
CAS number
9004-61-9
Weight
Average: 776.6486
Monoisotopic: 776.233485724
Chemical Formula
C28H44N2O23
InChI Key
KIUKXJAPPMFGSW-MNSSHETKSA-N
InChI
InChI=1S/C28H44N2O23/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45)/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18?,19?,20+,21+,22+,25-,26+,27-,28-/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-3-{[(2S,3R,5S,6R)-4-{[(2R,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-{[(2R,3R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid
SMILES

Pharmacology

Indication

Used to treat knee pain in patients with joint inflammation (osteoarthritis). It is usually used in patients who have not responded to other treatments such as acetaminophen, exercise, or physical therapy. Hyaluronic acid may also be used in plastic surgery to reduce wrinkles on the face or as a filler in other parts of the body. May be used in ophthalmology to assist in the extraction of cataracts, the implantation of intraocular lenses, corneal transplants, glaucoma filtration, retinal attachment and in the treatment of dry eyes. Finally, hyaluronic acid is also used to coat the bladder lining in treating interstitial cystitis.

Structured Indications
Not Available
Pharmacodynamics

Hyaluronic acid is similar to a substance that occurs naturally in the joints. It may work by acting as a lubricant and shock absorber in the joint, helping the knee to move smoothly, thereby lessening pain.

Mechanism of action

Hyaluronic acid functions as a tissue lubricant and is thought to play an important role in modulating the interactions between adjacent tissues. Hyaluronic acid is a polysaccharide which is distributed widely in the extracellular matrix of connective tissue in man. It forms a viscoelastic solution in water which makes it suitable for aqueous and vitreous humor in ophthalmic surgery. Mechanical protection for tissues (iris, retina) and cell layers (corneal, endothelium, and epithelium) are provided by the high viscosity of the solution. Elasticity of the solution assists in absorbing mechanical stress and providing a protective buffer for tissues. This viscoelasticity enables maintenance of a deep chamber during surgical manipulation since the solution does not flow out of the open anterior chamber. In facilitating wound healing, it is thought that it acts as a protective transport vehicle, taking peptide growth factors and other structural proteins to a site of action. It is then enzymatically degraded and active proteins are released to promote tissue repair. Hyaluronic acid is being used intra-articularly to treat osteoarthritis. Cell receptors that have been identified for hyaluronic acid fall into three main groups: CD44, Receptor for Hyaluronan-mediated motility (RHAMM) and intracellular adhesion molecule-1 (ICAM-1).

CD44 mediates cell interaction with hyaluronic acid and the binding of the two functions as an important part in various physiologic events, such as cell aggregation, migration, proliferation and activation; cell-cell and cell-substrate adhesion; endocytosis of hyaluronic acid, which leads to hyaluronic acid catabolism in macrophages; and assembly of petircellular matrices from HA and proteoglycan. CD44 has two important roles in skin, regulation of keratinocyte proliferation in response to extracellular stimuli and the maintenance of local hyaluronic acid homeostasis.

ICAM-1 is known mainly as a metabolic cell surface receptor for hyaluronic acid, and this protein may be responsible mainly for the clearance of hyaluronic acid from lymph and blood plasma, which accounts for perhaps most of its whole-body turnover. Ligand binding of this receptor, thus, triggers a highly coordinated cascade of events that includes the formation of an endocytotic vesicle, its fusion with primary lysosomes, enzymatic digestion to monosaccharides, active transmembrane transport of these sugars to cell sap, phosphorylation of GlcNAc and enzymatic deacetylation. ICAM-1 may also serve as a cell adhesion molecule, and the binding of hyaluronic acid to ICAM-1 may contribute to the control of ICAM-1-mediated inflammatory activation.

TargetActionsOrganism
ACD44 antigenNot AvailableHuman
AIntercellular adhesion molecule 1Not AvailableHuman
AHyaluronan mediated motility receptorNot AvailableHuman
UNeurocan core protein
binder
Human
UVersican core protein
binder
Human
UComplement component 1 Q subcomponent-binding protein, mitochondrial
binder
Human
UHyaluronan and proteoglycan link protein 1
binder
Human
UHyaluronan and proteoglycan link protein 3
binder
Human
UHyaluronan and proteoglycan link protein 4
binder
Human
UHyaluronan-binding protein 2
binder
Human
ULayilin
binder
Human
UStabilin-2
binder
Human
UTumor necrosis factor-inducible gene 6 protein
binder
Human
UInterphotoreceptor matrix proteoglycan 2
binder
Human
UIntracellular hyaluronan-binding protein 4
binder
Human
Absorption

Hyaluronic acid is absorbed and diffuses slowly out of the injection site.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hyaluronic acid is degraded by a family of enzymes called hyaluronidases.

Route of elimination

Hyaluronic acid is eliminated via the canal of Schlemm.

Half life
Not Available
Clearance
Not Available
Toxicity

>2400 mg/kg (mouse, oral, sodium salt) >4000 mg/kg (mouse, subcutaneous, sodium salt) 1500 mg/kg (mouse, intraperitoneal, sodium salt)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

Synthesis Reference

Susan Hockfield, Diane M. Jaworski, "DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides." U.S. Patent US5635370, issued June 03, 1997.

US5635370
General References
Not Available
External Links
Human Metabolome Database
HMDB10366
KEGG Drug
D08043
KEGG Compound
C00518
PubChem Compound
24759
PubChem Substance
310264899
ChemSpider
23145
PharmGKB
PA165958431
Wikipedia
Sodium_hyaluronate
ATC Codes
S01KA01 — Hyaluronic acidM09AX01 — Hyaluronic acidS01KA51 — Hyaluronic acid, combinationsR01AX09 — Hyaluronic acidD03AX05 — Hyaluronic acid
MSDS
Download (19.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Unknown StatusPreventionTissue Adhesions1
0Unknown StatusTreatmentInsertional Achilles Tendinitis1
1Active Not RecruitingTreatmentImproved Healing of Scarred Vocal Folds / Improved Vocal Fold Function / Improved Vocal Fold Status1
1CompletedBasic SciencePain, Acute1
1Not Yet RecruitingTreatmentCarpal Tunnel Syndrome (CTS)1
1Not Yet RecruitingTreatmentSenescence Wrinkles, Acne, Pitting Scar1
1RecruitingTreatmentIntra-articular Injection / Osteoarthritis (OA) / Pain Syndrome1
1, 2Active Not RecruitingTreatmentOsteoarthritis (OA)1
1, 2CompletedTreatmentAlveolar Bone Losses1
1, 2CompletedTreatmentAnterior Cruciate Ligament Injury / Osteoarthritis (OA)1
1, 2CompletedTreatmentArthritis of Knee / Knee Osteoarthritis (Knee OA)1
1, 2CompletedTreatmentOsteoarthritis (OA)1
1, 2CompletedTreatmentRecovery Following Partial Medial Meniscectomy1
1, 2Not Yet RecruitingTreatmentIntervertebral Disc Degeneration1
1, 2RecruitingTreatmentDegenerative Arthritis / Degenerative Joint Disease / Joint Disease / Knee Osteoarthritis (Knee OA) / Osteoarthritis (OA) / Osteoarthrosis Deformans1
2Active Not RecruitingTreatmentMSC / Osteoarthritis (OA) / Stem Cells1
2CompletedNot AvailableOsteoarthritis (OA)1
2CompletedBasic ScienceDry Eye Syndrome (DES)1
2CompletedTreatmentArticular Cartilage Disorder of Knee1
2CompletedTreatmentConjunctivitis, Bacterial1
2CompletedTreatmentDry Eye Syndromes1
2CompletedTreatmentHard of Hearing1
2CompletedTreatmentKeratoconjunctival Epithelial Disorder1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)2
2CompletedTreatmentKnee Osteoarthrosis1
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentPoisoning by BCG Vaccine1
2Enrolling by InvitationTreatmentDehydration1
2Not Yet RecruitingSupportive CareArthralgia / Breast Neoplasm Female1
2RecruitingTreatmentArticular Cartilage Disorder of Knee / Articular Cartilage; Degeneration1
2RecruitingTreatmentDefect of Articular Cartilage / Knee Osteoarthritis (Knee OA)1
2Unknown StatusPreventionOsteoarthritis (OA)1
2Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2, 3CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2, 3RecruitingTreatmentTrigger Digit1
2, 3Unknown StatusTreatmentKnee Osteoarthritis (Knee OA)1
2, 3Unknown StatusTreatmentSubacromial Impingement Syndrome1
3CompletedNot AvailableEye Dryness1
3CompletedTreatmentDry Eye Syndrome (DES)2
3CompletedTreatmentDry Eye Syndromes1
3CompletedTreatmentKnee Osteoarthritis (Knee OA)3
3CompletedTreatmentOral Submucous Fibrosis1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentOsteoarthritis of Shoulder1
3Not Yet RecruitingTreatmentPost Operative Adhesions1
3RecruitingTreatmentDry Eye Syndrome (DES)1
3RecruitingTreatmentLateral Epicondylitis1
3TerminatedNot AvailableKnee Osteoarthritis (Knee OA)1
3TerminatedTreatmentSymptomatic Hip Osteoarthritis1
3Unknown StatusTreatmentOsteoarthritis, Hip1
4Active Not RecruitingBasic ScienceKnee Osteoarthritis (Knee OA)1
4Active Not RecruitingOtherKnee Osteoarthritis (Knee OA)1
4CompletedNot AvailableEye Dryness1
4CompletedTreatmentAntiseptic Gel / Bacterial Growth / Bioadhesive Gel / Chistosan / Clorhexidine Gel Bacteria / Clorhexidine-chitosan / Surgery, Oral / Suture Bacteria / Third Molar Surgery / Wisdom Teeth1
4CompletedTreatmentArthrocentesis / Pain / Temporomandibular Joint Dysfunction1
4CompletedTreatmentCorneal Edema / Intraocular Pressure1
4CompletedTreatmentDry Eye Syndromes2
4CompletedTreatmentDry Eye Syndromes / Keratoconjunctivitis Sicca2
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentMeniscus Lesion1
4CompletedTreatmentMenopause / Vaginal Dryness1
4CompletedTreatmentOsteoarthritis (OA)5
4CompletedTreatmentPeri-Implantitis1
4CompletedTreatmentPeriodontitis1
4CompletedTreatmentWound Healing Complication1
4Not Yet RecruitingTreatmentCartilage Damage1
4RecruitingTreatmentDiabetes Mellitus (DM) / Dry Eye Syndromes1
4RecruitingTreatmentDry Eye Syndrome (DES)1
4RecruitingTreatmentDry Eye Syndromes / Meibomian Gland Dysfunction (MGD)1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)3
4RecruitingTreatmentNon-Insertional Achilles Tendinopathy / Plantaris Friction Syndrome1
4RecruitingTreatmentOsteoarthritis (OA) / Shoulder Pain1
4RecruitingTreatmentOsteoarthritis, Hip1
4RecruitingTreatmentThyroid Eye Disease1
4Unknown StatusEducational/Counseling/TrainingKnee Osteoarthritis (Knee OA)1
4WithdrawnPreventionUrinary Tract Infections (UTIs)1
Not AvailableActive Not RecruitingTreatmentDeficiency of Anterior Cruciate Ligament1
Not AvailableCompletedNot AvailableMesothelioma1
Not AvailableCompletedNot AvailableOsteoarthritis (OA)3
Not AvailableCompletedTreatmentAnkle Osteoarthritis1
Not AvailableCompletedTreatmentCarpal Tunnel Syndrome (CTS) / Pain, Chronic1
Not AvailableCompletedTreatmentChronic Periodontitis With Infra-bony Defects1
Not AvailableCompletedTreatmentDry Eye Syndromes1
Not AvailableCompletedTreatmentEye Dryness1
Not AvailableCompletedTreatmentInterdental Papilla Augmentation1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentOsteoarthritis (OA)1
Not AvailableCompletedTreatmentPatients With Dental Extraction1
Not AvailableCompletedTreatmentShoulder Pain / Subacromial Bursitis / Subdeltoid Bursitis1
Not AvailableCompletedTreatmentTransplantation, Corneal1
Not AvailableCompletedTreatmentTrigger Finger1
Not AvailableNot Yet RecruitingNot AvailableOsteoarthritis (OA)1
Not AvailableNot Yet RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableNot Yet RecruitingTreatmentPeriarthritis1
Not AvailableRecruitingNot AvailableOsteoarthritis (OA)1
Not AvailableRecruitingTreatmentAdhesive Capsulitis1
Not AvailableRecruitingTreatmentAge-related Cataract1
Not AvailableRecruitingTreatmentKnee Osteoarthritis (Knee OA)2
Not AvailableRecruitingTreatmentKnee Osteoarthritis (Knee OA) / Synovitis of Knee1
Not AvailableRecruitingTreatmentRotator Cuff Injuries / Shoulder Pain / Strokes1
Not AvailableRecruitingTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableRecruitingTreatmentTreatment Resistant Carpal Tunnel in RA Patients1
Not AvailableUnknown StatusTreatmentGlaucoma / Ocular Surface Disease1
Not AvailableWithdrawnTreatmentKnee Osteoarthritis (Knee OA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
PatchTopical
CreamTopical
PatchTopical6.1 g/100mg
CreamTopical.15 g/50mL
Injection, solutionIntra-articular
GelTopical3.5 mg/mL
PatchTopical1.14 g/41
GelTopical2.5 g/100g
PatchTopical99.97 g/100g
PatchTopical67.9 mg/70mg
SolutionTopical.01 mL/100mL
SolutionTopical.01 g/100mL
GelTopical1000 g/20mL
LiquidTopical100 g/100mL
PatchTopical.056 g/100mL
PatchTopical99 g/100g
GelTopical.1 mg/mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityEasily soluble in cold water. Insoluble in organic solvents.Not Available
Predicted Properties
PropertyValueSource
Water Solubility46.6 mg/mLALOGPS
logP-1.8ALOGPS
logP-8.2ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)2.87ChemAxon
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count23ChemAxon
Hydrogen Donor Count14ChemAxon
Polar Surface Area399.71 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity155.1 m3·mol-1ChemAxon
Polarizability70.56 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acylaminosugars. These are organic compounds containing a sugar linked to a chain through N-acyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Acylaminosugars
Alternative Parents
Oligosaccharides / Fatty acyl glycosides / N-acyl-alpha-hexosamines / O-glucuronides / O-glycosyl compounds / Beta hydroxy acids and derivatives / Dicarboxylic acids and derivatives / Pyrans / Oxanes / Acetamides
show 13 more
Substituents
Oligosaccharide / Acylaminosugar / Fatty acyl glycoside / N-acyl-alpha-hexosamine / 1-o-glucuronide / O-glucuronide / Glucuronic acid or derivatives / Glycosyl compound / O-glycosyl compound / Beta-hydroxy acid
show 25 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Hyalurononglucosaminidase activity
Specific Function
Receptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix interactions through its affinity for HA, and possibly also through its affinity for other ligands such as osteopontin, collage...
Gene Name
CD44
Uniprot ID
P16070
Uniprot Name
CD44 antigen
Molecular Weight
81537.025 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Virus receptor activity
Specific Function
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial api...
Gene Name
ICAM1
Uniprot ID
P05362
Uniprot Name
Intercellular adhesion molecule 1
Molecular Weight
57824.785 Da
References
  1. Comper, Wayne D. (1996). Extracellular Matrix (2nd ed.). CRC Press LLC. [ISBN:3718658437]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Hyaluronic acid binding
Specific Function
Involved in cell motility. When hyaluronan binds to HMMR, the phosphorylation of a number of proteins, including PTK2/FAK1 occurs. May also be involved in cellular transformation and metastasis for...
Gene Name
HMMR
Uniprot ID
O75330
Uniprot Name
Hyaluronan mediated motility receptor
Molecular Weight
84099.845 Da
References
  1. Turley EA: Purification of a hyaluronate-binding protein fraction that modifies cell social behavior. Biochem Biophys Res Commun. 1982 Oct 15;108(3):1016-24. [PubMed:6185115]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Hyaluronic acid binding
Specific Function
May modulate neuronal adhesion and neurite growth during development by binding to neural cell adhesion molecules (NG-CAM and N-CAM). Chondroitin sulfate proteoglycan; binds to hyaluronic acid.
Gene Name
NCAN
Uniprot ID
O14594
Uniprot Name
Neurocan core protein
Molecular Weight
143092.14 Da
References
  1. Prange CK, Pennacchio LA, Lieuallen K, Fan W, Lennon GG: Characterization of the human neurocan gene, CSPG3. Gene. 1998 Oct 23;221(2):199-205. [PubMed:9795216]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Hyaluronic acid binding
Specific Function
May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid.
Gene Name
VCAN
Uniprot ID
P13611
Uniprot Name
Versican core protein
Molecular Weight
372816.875 Da
References
  1. Perides G, Lane WS, Andrews D, Dahl D, Bignami A: Isolation and partial characterization of a glial hyaluronate-binding protein. J Biol Chem. 1989 Apr 5;264(10):5981-7. [PubMed:2466833]
  2. Bignami A, Lane WS, Andrews D, Dahl D: Structural similarity of hyaluronate binding proteins in brain and cartilage. Brain Res Bull. 1989 Jan;22(1):67-70. [PubMed:2469524]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Transcription factor binding
Specific Function
Is believed to be a multifunctional and multicompartmental protein involved in inflammation and infection processes, ribosome biogenesis, regulation of apoptosis, transcriptional regulation and pre...
Gene Name
C1QBP
Uniprot ID
Q07021
Uniprot Name
Complement component 1 Q subcomponent-binding protein, mitochondrial
Molecular Weight
31361.935 Da
References
  1. Yadav G, Prasad RL, Jha BK, Rai V, Bhakuni V, Datta K: Evidence for inhibitory interaction of hyaluronan-binding protein 1 (HABP1/p32/gC1qR) with Streptococcus pneumoniae hyaluronidase. J Biol Chem. 2009 Feb 6;284(6):3897-905. doi: 10.1074/jbc.M804246200. Epub 2008 Nov 11. [PubMed:19004836]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Hyaluronic acid binding
Specific Function
Stabilizes the aggregates of proteoglycan monomers with hyaluronic acid in the extracellular cartilage matrix.
Gene Name
HAPLN1
Uniprot ID
P10915
Uniprot Name
Hyaluronan and proteoglycan link protein 1
Molecular Weight
40165.215 Da
References
  1. Spicer AP, Joo A, Bowling RA Jr: A hyaluronan binding link protein gene family whose members are physically linked adjacent to chondroitin sulfate proteoglycan core protein genes: the missing links. J Biol Chem. 2003 Jun 6;278(23):21083-91. Epub 2003 Mar 27. [PubMed:12663660]
  2. Arming S, Strobl B, Wechselberger C, Kreil G: In vitro mutagenesis of PH-20 hyaluronidase from human sperm. Eur J Biochem. 1997 Aug 1;247(3):810-4. [PubMed:9288901]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Hyaluronic acid binding
Specific Function
May function in hyaluronic acid binding.
Gene Name
HAPLN3
Uniprot ID
Q96S86
Uniprot Name
Hyaluronan and proteoglycan link protein 3
Molecular Weight
40893.995 Da
References
  1. Spicer AP, Joo A, Bowling RA Jr: A hyaluronan binding link protein gene family whose members are physically linked adjacent to chondroitin sulfate proteoglycan core protein genes: the missing links. J Biol Chem. 2003 Jun 6;278(23):21083-91. Epub 2003 Mar 27. [PubMed:12663660]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Hyaluronic acid binding
Specific Function
Binds to hyaluronic acid and may be involved in formation of the extracellular matrix.
Gene Name
HAPLN4
Uniprot ID
Q86UW8
Uniprot Name
Hyaluronan and proteoglycan link protein 4
Molecular Weight
42801.105 Da
References
  1. Spicer AP, Joo A, Bowling RA Jr: A hyaluronan binding link protein gene family whose members are physically linked adjacent to chondroitin sulfate proteoglycan core protein genes: the missing links. J Biol Chem. 2003 Jun 6;278(23):21083-91. Epub 2003 Mar 27. [PubMed:12663660]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serine-type endopeptidase activity
Specific Function
Cleaves the alpha-chain at multiple sites and the beta-chain between 'Lys-53' and 'Lys-54' but not the gamma-chain of fibrinogen and therefore does not initiate the formation of the fibrin clot and...
Gene Name
HABP2
Uniprot ID
Q14520
Uniprot Name
Hyaluronan-binding protein 2
Molecular Weight
62671.255 Da
References
  1. Choi-Miura NH, Tobe T, Sumiya J, Nakano Y, Sano Y, Mazda T, Tomita M: Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. J Biochem. 1996 Jun;119(6):1157-65. [PubMed:8827452]
  2. Choi-Miura NH, Yoda M, Saito K, Takahashi K, Tomita M: Identification of the substrates for plasma hyaluronan binding protein. Biol Pharm Bull. 2001 Feb;24(2):140-3. [PubMed:11217080]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Hyaluronic acid binding
Specific Function
Receptor for hyaluronate.
Gene Name
LAYN
Uniprot ID
Q6UX15
Uniprot Name
Layilin
Molecular Weight
43108.055 Da
References
  1. Bono P, Rubin K, Higgins JM, Hynes RO: Layilin, a novel integral membrane protein, is a hyaluronan receptor. Mol Biol Cell. 2001 Apr;12(4):891-900. [PubMed:11294894]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Scavenger receptor activity
Specific Function
Phosphatidylserine receptor that enhances the engulfment of apoptotic cells. Hyaluronan receptor that binds to and mediates endocytosis of hyaluronic acid (HA). Acts also, in different species, as ...
Gene Name
STAB2
Uniprot ID
Q8WWQ8
Uniprot Name
Stabilin-2
Molecular Weight
276985.63 Da
References
  1. Politz O, Gratchev A, McCourt PA, Schledzewski K, Guillot P, Johansson S, Svineng G, Franke P, Kannicht C, Kzhyshkowska J, Longati P, Velten FW, Johansson S, Goerdt S: Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues. Biochem J. 2002 Feb 15;362(Pt 1):155-64. [PubMed:11829752]
  2. Zhou B, McGary CT, Weigel JA, Saxena A, Weigel PH: Purification and molecular identification of the human hyaluronan receptor for endocytosis. Glycobiology. 2003 May;13(5):339-49. Epub 2002 Dec 17. [PubMed:12626425]
  3. Harris EN, Kyosseva SV, Weigel JA, Weigel PH: Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J Biol Chem. 2007 Feb 2;282(5):2785-97. Epub 2006 Dec 4. [PubMed:17145755]
  4. Harris EN, Weigel JA, Weigel PH: The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin. J Biol Chem. 2008 Jun 20;283(25):17341-50. doi: 10.1074/jbc.M710360200. Epub 2008 Apr 22. [PubMed:18434317]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Hyaluronic acid binding
Specific Function
Possibly involved in cell-cell and cell-matrix interactions during inflammation and tumorigenesis.
Gene Name
TNFAIP6
Uniprot ID
P98066
Uniprot Name
Tumor necrosis factor-inducible gene 6 protein
Molecular Weight
31203.09 Da
References
  1. Wisniewski HG, Burgess WH, Oppenheim JD, Vilcek J: TSG-6, an arthritis-associated hyaluronan binding protein, forms a stable complex with the serum protein inter-alpha-inhibitor. Biochemistry. 1994 Jun 14;33(23):7423-9. [PubMed:7516184]
  2. Lee TH, Wisniewski HG, Vilcek J: A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J Cell Biol. 1992 Jan;116(2):545-57. [PubMed:1730767]
  3. Kohda D, Morton CJ, Parkar AA, Hatanaka H, Inagaki FM, Campbell ID, Day AJ: Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration. Cell. 1996 Sep 6;86(5):767-75. [PubMed:8797823]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Hyaluronic acid binding
Specific Function
Chondroitin sulfate- and hyaluronan-binding proteoglycan involved in the organization of interphotoreceptor matrix; may participate in the maturation and maintenance of the light-sensitive photorec...
Gene Name
IMPG2
Uniprot ID
Q9BZV3
Uniprot Name
Interphotoreceptor matrix proteoglycan 2
Molecular Weight
138619.39 Da
References
  1. Acharya S, Foletta VC, Lee JW, Rayborn ME, Rodriguez IR, Young WS 3rd, Hollyfield JG: SPACRCAN, a novel human interphotoreceptor matrix hyaluronan-binding proteoglycan synthesized by photoreceptors and pinealocytes. J Biol Chem. 2000 Mar 10;275(10):6945-55. [PubMed:10702256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Not Available
Specific Function
May be involved in nuclear functions such as the remodeling of chromatin and the regulation of transcription.
Gene Name
HABP4
Uniprot ID
Q5JVS0
Uniprot Name
Intracellular hyaluronan-binding protein 4
Molecular Weight
45785.09 Da
References
  1. Huang L, Grammatikakis N, Yoneda M, Banerjee SD, Toole BP: Molecular characterization of a novel intracellular hyaluronan-binding protein. J Biol Chem. 2000 Sep 22;275(38):29829-39. [PubMed:10887182]

Drug created on February 23, 2012 11:15 / Updated on November 09, 2017 04:41